Primate liver outperformed primate esophagus at the screening dilution in EmA testing

Endomysial antibody testing remains one of the most trusted serologic tools in celiac disease, but the traditional primate esophagus substrate carries familiar laboratory problems: tissue scarcity, inconsistent section quality, difficult pattern interpretation, and pressure to reduce animal use. In this head-to-head comparison, primate liver emerged as a practical alternative that preserved the core diagnostic behavior of the assay while improving detection at the screening dilution. The tTG-transfected cell-based assay went a step further, identifying every celiac disease-positive sample at 1:10.

The performance gap appeared early and plainly. Among 54 celiac disease-positive samples, primate esophagus identified 40 as positive at 1:10, or 74.1%. Primate liver identified 52 of 54, or 96.3%, and the tTG-transfected cell-based assay identified all 54. For the 62 non-celiac control samples, primate esophagus produced no reactive results, while primate liver and the cell-based assay each produced one reactive control sample. A single false-positive result can matter in a reference assay, especially one used to refine prebiopsy probability, but the broader pattern still favored liver as the more sensitive tissue substrate.

Sensitivity rose sharply when liver replaced esophagus

The study’s design was straightforward and clinically relevant. Investigators compared three substrates in parallel: primate esophagus as the historical reference, primate liver as the proposed alternative, and a tTG-transfected cell-based assay intended to mimic the autoimmune target more directly. Samples came from adults with serologically defined celiac disease and from non-celiac controls, including autoimmune liver disease, symptomatic controls, and healthy participants. Readers were blinded to the original classification, limiting interpretation bias in the fluorescence calls.

At the screening dilution, the better performance of liver was not subtle. Of the 14 celiac disease-positive samples missed by esophagus, liver reclassified 12 as positive, while the cell-based assay reclassified all 14. In practical terms, that means the liver substrate captured most of the cases that the traditional esophageal tissue failed to flag at first pass. The assay’s diagnostic logic makes this result biologically plausible: endomysial antibodies are directed against tissue transglutaminase-related structures, and liver provides abundant tTG-rich architecture that may better expose the relevant fluorescence pattern than multilayered esophageal tissue.

Parallel titer decline across all three substrates suggests shared biology

The differences narrowed as titers fell. Across serial dilutions, positivity declined in parallel on all substrates, with 59.3% to 68.5% positivity at 1:100 and 18.5% to 24.1% at 1:1000, with overlapping confidence intervals. That pattern argues against a wholly separate analytical behavior for the liver substrate. Instead, it suggests that all three methods are reading the same immunologic signal, but with different efficiency at the lower end of detection.

The consequence is important for routine laboratory practice. When antibody levels are high, nearly any reasonable substrate will likely identify a positive sample. When titers are lower, the substrate choice becomes decisive. A more sensitive screening substrate can reduce the number of falsely negative results that fall through the cracks before confirmatory testing or biopsy is considered. In celiac disease, where serology often drives downstream decisions about endoscopy, diet counseling, and further workup, that difference has direct bedside implications.

The one reactive control sample seen with primate liver and the cell-based assay deserves attention, but it does not erase the overall performance signal. It does, however, reinforce the need for careful clinical correlation, especially in patients with autoimmune liver disease, where serologic cross-reactivity is part of the diagnostic terrain. A highly sensitive assay must still preserve enough specificity to avoid triggering unnecessary downstream evaluation.

A cell-based assay with tTG expression may fit as a confirmatory platform

The strongest results came from the tTG-transfected cell-based assay. It identified every celiac disease-positive sample at screening dilution and matched liver in negative agreement except for the same single reactive control. In a mechanistic sense, that is unsurprising. By displaying human tissue transglutaminase in a controlled cellular system, the assay may offer a cleaner antigenic target than tissue sections, where architecture and background staining can complicate interpretation.

This does not mean the cell-based assay should replace tissue-based EmA testing outright. Tissue sections remain familiar to many laboratories, and primate esophagus has decades of validation behind it. The more realistic role for the cell-based platform is as a complementary confirmatory tool, especially when tissue substrate quality is inconsistent or when the fluorescence pattern is ambiguous. In that setting, the assay may help adjudicate borderline samples without replacing the entire workflow.

The practical appeal of primate liver is scalability, not novelty

Laboratory adoption often hinges less on theoretical performance than on reproducibility, supply, and workflow stability. Primate liver has an advantage on all three counts. It is more scalable than primate esophagus, less dependent on the fragile histologic structure of multilayered esophageal tissue, and easier to standardize in a commercial assay format. It also reduces reliance on animal tissues that are harder to source consistently. Those operational issues are not peripheral; they determine whether a diagnostic platform can be deployed broadly and maintained over time.

The findings align with prior reports suggesting that liver can perform well in celiac disease testing, including pediatric and adult cohorts. Here, the adult data extend that signal by showing direct parallel comparison with both esophagus and a tTG-based cellular platform. The agreement profile is strong enough to support primate liver as a realistic substitute substrate for EmA immunofluorescence, particularly in settings where esophagus is unavailable or variable.

One sentence captures the main diagnostic shift: primate liver picked up substantially more celiac disease-positive samples at the screening dilution than primate esophagus did.

Histology-linked validation remains the next step

The study is persuasive, but it is not the final word. Sample size was modest, the controls were drawn from mixed clinical categories, and the analysis relied on serologic classification rather than histology-linked outcome adjudication for every case. Larger multicenter studies will need to test whether the apparent gain in sensitivity holds across broader laboratory settings and whether the small specificity tradeoff remains acceptable when compared against biopsy-confirmed disease status.

The publication therefore leaves one clinically useful conclusion and one open question. Primate liver looks ready to function as a scalable alternative to primate esophagus in EmA-IFA, and the tTG-transfected cell-based assay appears well suited to complement it. What still needs proof is how these substrates perform in routine care when the diagnostic truth is anchored to mucosal histology, mixed autoimmune backgrounds, and the full range of titers seen in everyday celiac disease workups.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA